ArticleUrology practice2025
Development of a Patient Decision Aid for cT1 Renal Masses: A User-Centered Mixed-Methods Study.
Article in Urology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt is important to actively involve patients with cT1 renal masses in treatment decision-making. Patient decision aids (PtDAs) support patients and health care professionals (HCPs) in shared decision-making. The aim of this study was to develop a Dutch PtDA for cT1 renal masses and to test its acceptability and usability.
methodsThis was a user-centered mixed-methods design. Cocreation process with HCPs from several hospitals and a patient representative, with input from (a) a needs assessment study (semistructured interviews and questionnaires) and (b) acceptability and usability testing (think-aloud sessions and semistructured interviews), guided by the International Patient Decision Aids Standards (IPDAS) criteria. Compatibility with the IPDAS criteria was evaluated (c).
resultsIn total, 12 patients with cT1 renal masses and 56 HCPs participated. The PtDA consists of 3 components: (1) a decision aid handout demonstrating an overview of treatment options; (2) an online decision aid with information on renal cell carcinoma, treatment options, and values-clarification exercises; and (3) a personal decision aid summary. Both patients and HCPs highly appreciated the PtDA and were able to navigate through it. The PtDA fulfills all 12 IPDAS criteria.
conclusionsWe systematically developed a PtDA for cT1 renal masses. The PtDA was found acceptable and usable by patients and HCPs. The PtDA is currently being implemented in routine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.